Progenity (PROG) Stock Price
Progenity Price
Revenue at Progenity has contracted by 78.6% per year over the past 3 years to 1.25 M USD. For Progenity, the net margin of -19,840.6% is down versus -100.9% a few years ago. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Progenity stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Progenity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Progenity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Progenity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Progenity Price |
|---|
Progenity Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Progenity Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|
| 127.00 | 143.00 | 74.00 | 1.00 | – | – | – | – | – |
| – | 12.60 | -48.25 | -98.65 | – | – | – | – | – |
| 27.56 | 30.07 | -25.68 | 100.00 | – | – | – | – | – |
| 35.00 | 43.00 | -19.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| -116.00 | -140.00 | -195.00 | -166.00 | -78.00 | -83.00 | -92.00 | -83.00 | -76.00 |
| -91.34 | -97.90 | -263.51 | -16,600.00 | – | – | – | – | – |
| -129.00 | -148.00 | -192.00 | -247.00 | -77.00 | -68.00 | -95.00 | -92.00 | -90.00 |
| – | 14.73 | 29.73 | 28.65 | -68.83 | -11.69 | 39.71 | -3.16 | -2.17 |
| 166.07 | 35.06 | 49.29 | 166.07 | 166.07 | 166.07 | 166.07 | 166.07 | 166.07 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Progenity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Progenity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Progenity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Progenity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Progenity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Progenity stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Progenity Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Progenity business model & stock analysis
Progenity SWOT Analysis
Strengths
Progenity Inc possesses several strengths that contribute to its competitive advantage in the market. These include:
- Advanced technology and expertise in genetic testing and diagnostics.
- Strong intellectual property portfolio, providing a barrier to entry for competitors.
- Wide range of testing services, catering to various medical specialties.
- Commitment to research and development, ensuring innovation and continuous improvement.
- Strong relationships with healthcare providers and strategic partnerships, facilitating market reach.
Weaknesses
Despite its strengths, Progenity Inc also faces certain weaknesses that may impede its growth and market position:
- Reliance on third-party payers for reimbursement, which can lead to pricing pressure.
- Need for regulatory approvals for new tests, potentially causing delays in market entry.
- High research and development costs, affecting profitability.
- Intense competition from established players and emerging companies in the genetic testing industry.
- Dependence on key personnel for strategic decision-making and operations.
Opportunities
Progenity Inc can leverage several opportunities to expand its business and enhance its market position:
- Increasing demand for genetic testing due to advancements in precision medicine.
- Growing awareness and acceptance of non-invasive prenatal testing.
- Expansion into international markets to tap into a broader customer base.
- Collaboration with pharmaceutical companies for companion diagnostics development.
- Development of personalized medicine solutions, aligned with the trend of individualized healthcare.
Threats
Progenity Inc faces certain threats that could potentially hinder its growth and sustainability:
- Stringent regulations and compliance requirements governing genetic testing.
- Potential privacy and ethical concerns surrounding genetic data.
- Price sensitivity of customers and payers, leading to downward pressure on testing fees.
- Emergence of alternative technologies and methodologies for genetic testing.
- Political and economic uncertainties impacting healthcare spending and reimbursement policies.
Progenity Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Progenity historical P/E ratio, EBIT multiple, and P/S ratio
Progenity annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Progenity shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Progenity forecasts and price targets in August 2026
Analyst Price Targets 2026Progenity Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 10/14/2021 | Maintained | Buy | – | |
| 6/3/2021 | Downgrade | OutperformPerform | 74 | |
| 6/3/2021 | Downgrade | OutperformNeutral | – | |
| 5/17/2021 | Maintained | Underweight | 56 | |
| 5/14/2021 | Maintained | Outperform | 74 | |
| 2/8/2021 | Downgrade | OverweightUnderweight | 56 | |
| 11/10/2020 | Maintained | Outperform | 74 | |
| 10/23/2020 | Maintained | Buy | – | |
| 7/14/2020 | Maintained | Overweight | 56 | |
| 7/14/2020 | Maintained | Outperform | 74 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Progenity Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/27/2023 | -0.13USD | - | 0.00USD | - | 2022 Q4 |
| 11/8/2022 | -0.11USD | - | 0.00USD | - | 2022 Q3 |
| 8/10/2022 | -0.12USD | - | 0.00USD | - | 2022 Q2 |
| 5/10/2022 | -0.13USD | - | 0.00USD | - | 2022 Q1 |
| 3/28/2022 | -0.16USD | - | 253,749.00USD | - | 2021 Q4 |
| 11/10/2021 | -0.46USD | - | 3.86 MUSD | - | 2021 Q3 |
| 8/12/2021 | -0.82USD | - | 19.00 MUSD | - | 2021 Q2 |
| 5/13/2021 | -0.83USD | - | 25.78 MUSD | - | 2021 Q1 |
| 3/18/2021 | -0.84USD | - | 25.09 MUSD | - | 2020 Q4 |
| 11/9/2020 | -0.73USD | - | 35.27 MUSD | - | 2020 Q3 |
Progenity Supply Chain
Progenity Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.65 | -0.32 | 0.78 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.70 | 0.36 | -0.13 |
Frequently asked questions about Progenity
The business model of Progenity Inc revolves around providing innovative diagnostic solutions and precision medicine to improve patient care and outcomes. Progenity leverages its expertise in genomics, molecular biology, and bioinformatics to develop and commercialize specialized tests and diagnostic tools. The company offers a diverse range of services, including genetic testing, carrier screening, prenatal and reproductive health testing, and oncology testing. By combining advanced technologies and clinical expertise, Progenity aims to empower healthcare providers with actionable insights for personalized medicine, early disease detection, and tailored treatment plans. Progenity Inc is committed to revolutionizing patient care through its advanced diagnostic solutions and partnerships with healthcare professionals.
Progenity Inc is primarily active in the healthcare industry.
The main competitors of Progenity Inc in the market include companies such as Invitae Corporation, Guardant Health, Inc., and Natera, Inc.
Progenity Inc is a prominent company in the healthcare industry, focusing on personalized medicine and diagnostic solutions. Established in 2013, Progenity has quickly risen to prominence due to its innovative products and commitment to improving patient care. With a particular emphasis on genomic testing and precision medicine, Progenity offers a wide range of diagnostic tests, including prenatal and genetic screening. The company's comprehensive approach to healthcare has garnered recognition and partnerships with leading medical institutions. Progenity Inc continues to research, develop, and provide cutting-edge solutions that empower physicians and patients alike, promising a brighter future for personalized healthcare.
Progenity Inc, a leading biotechnology company, has achieved several significant milestones. It successfully completed its initial public offering in June 2020, raising over $122 million in gross proceeds. The company has also expanded its portfolio of innovative molecular testing solutions, empowering healthcare providers and patients with essential genetic insights. Progenity Inc's groundbreaking research and development efforts have resulted in the launch of its flagship product, the Innatal® Prenatal Test, which aids in the detection of common fetal chromosomal disorders. Furthermore, the company has forged strategic partnerships with key industry players, solidifying its position as a pioneer in the field of genetic testing.
Progenity Inc is primarily present in the United States.
Progenity Inc represents a values-driven corporate philosophy focused on improving patient outcomes through innovative molecular testing solutions. The company is committed to enabling personalized medicine, providing physicians and patients with actionable insights to make informed healthcare decisions. Progenity's mission revolves around empowering individuals with the knowledge they need to lead healthier lives. With their comprehensive suite of molecular diagnostic tests, Progenity aims to address unmet medical needs in the fields of women's health, organ transplantation, and gastrointestinal disorders. By leveraging cutting-edge technology and a patient-centric approach, Progenity strives to deliver accurate, timely, and reliable results for healthcare providers and their patients.
7 analysts currently rate the Progenity stock: 6 recommend buying, 1 holding and 0 selling.
The Progenity share (PROG) is listed on 4 stock exchanges, including: NASDAQ (PROG), Frankfurt (4ZU.F), München (4ZU.MU), Düsseldorf (4ZU.DU).
Progenity Inc is a leading company in prenatal diagnostics and personalized medicine. The company offers a wide range of products and services aimed at improving the health of mother and child during pregnancy and detecting genetic diseases or developmental disorders early on. Progenity Inc has several divisions, including the Progenity Testing Division, which specializes in non-invasive prenatal tests (NIPT), carrier screening, molecular testing, infertility diagnostics, and cancer diagnostics. Progenity's NIPT tests are highly accurate and provide reliable results regarding chromosomal abnormalities in the unborn child. These tests can be performed as early as the 10th week of pregnancy and only require a simple blood sample from the mother. Progenity's carrier screening tests identify genetic mutations that can be passed from parents to the unborn child and can lead to serious diseases. With this test, couples can determine if they are carriers of such mutations and assess the risk of their child developing these conditions. Progenity's molecular testing procedures allow doctors to identify the genetic causes of various diseases and plan more effective treatments. Progenity also offers comprehensive infertility diagnostics, allowing couples to identify the causes of their infertility and plan appropriate treatments. Progenity's Oncology Division offers a comprehensive range of genetic tests for cancer patients. These tests identify the genetic causes of specific types of cancer and enable the planning of individualized, personalized therapies. Progenity Inc also offers innovative solutions for reproductive health. The company has developed a unique platform called Eeva, which allows doctors to track the development of embryos in real time and select the best embryos for implantation. The Eeva platform improves the success rates of IVF treatments and reduces the likelihood of multiple pregnancies. Overall, Progenity Inc relies on innovative technologies and personalized medicine to improve the health of mother and child during pregnancy and facilitate the detection and treatment of genetic diseases. The company pursues a long-term strategy to continue its growth in this dynamic market and solidify its position as a leading company in prenatal diagnostics and personalized medicine.
The revenue cannot currently be calculated for Progenity.
The profit cannot currently be calculated for Progenity.
The P/E ratio cannot be calculated for Progenity at the moment.
The P/S cannot be calculated for Progenity currently.
The Eulerpool Quality Score for Progenity is 2/10.
The ISIN of Progenity is US74319F1075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Progenity is A2P7FX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Progenity is PROG. The ticker symbol is used to trade Progenity shares on the stock exchange.
Progenity is assigned to the 'Health' sector.
The dividends of Progenity are distributed in USD.
Progenity stock
Progenity Peer Group
Progenity Ticker
Progenity FIGI
All fundamentals and in-depth analysis of Progenity
Our stock analysis for Progenity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Progenity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.